Shorter oral treatment for drug-resistant tuberculosis
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and weigh at least 30 kg.
- You have active TB in your lungs that is resistant to rifampicin (a key antibiotic).
- Your TB must still be sensitive to at least one of the two antibiotics: moxifloxacin or levofloxacin.
- If you are a woman who can have children, you must not be pregnant and must use effective birth control during the study.
- If you are a man with a partner who can have children, you must use condoms or other effective birth control.
- You must be willing to have an HIV test and, if positive, take antiretroviral therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a shorter, all-pill (oral) treatment plan for people with rifampicin-resistant pulmonary tuberculosis. It aims to improve treatment while reducing the burden of therapy, using a plan tailored to the individual.
This study tests a shorter six-month treatment for tuberculosis that is resistant to rifampicin, a common antibiotic. The goal is to make treatment easier and possibly safer while still being effective.
This trial tests a shorter treatment regimen for people with tuberculosis (TB) who don't have symptoms. If you have TB bacteria in your lungs but no cough, fever, night sweats, or weight loss, this study may offer a more convenient treatment option.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This study tests a shorter-course treatment for tuberculosis (TB) in people 65 and older. It compares a new ultra-short regimen to the usual longer one, using the drugs bedaquiline, linezolid, and pyrazinamide, to see if a shorter treatment is just as effective and safer for older adults.
This study tests if a shorter course of tuberculosis (TB) medicine works as well as the current longer treatment for children. If successful, it means fewer days of medicine and fewer side effects for kids.
Hear when a new Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.